Analysts Anticipate Icon Plc (ICLR) to Post $1.32 EPS
Wall Street brokerages predict that Icon Plc (NASDAQ:ICLR) will post earnings per share of $1.32 for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Icon Plc’s earnings. The highest EPS estimate is $1.37 and the lowest is $1.27. Icon Plc reported earnings of $1.19 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.9%. The firm is scheduled to report its next quarterly earnings results before the market opens on Thursday, October 26th.
On average, analysts expect that Icon Plc will report full year earnings of $5.31 per share for the current fiscal year, with EPS estimates ranging from $5.28 to $5.37. For the next financial year, analysts forecast that the company will report earnings of $5.93 per share, with EPS estimates ranging from $5.83 to $6.06. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Icon Plc.
Icon Plc (NASDAQ:ICLR) last posted its earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The firm had revenue of $431.00 million during the quarter, compared to analyst estimates of $430.68 million. During the same quarter in the prior year, the business posted $1.14 EPS. The business’s revenue was up 5.0% compared to the same quarter last year.
Several research firms have recently issued reports on ICLR. Zacks Investment Research lowered Icon Plc from a “buy” rating to a “hold” rating in a research report on Thursday, September 7th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $122.00 price target on shares of Icon Plc in a research report on Tuesday, September 12th. Robert W. Baird reaffirmed a “buy” rating and issued a $123.00 price target on shares of Icon Plc in a research report on Thursday, October 12th. Bank of America Corporation began coverage on Icon Plc in a research report on Monday, September 11th. They issued a “buy” rating and a $128.00 price target for the company. Finally, ValuEngine raised Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $119.33.
Icon Plc (NASDAQ:ICLR) traded down 0.64% during mid-day trading on Friday, hitting $113.63. 282,713 shares of the stock traded hands. The firm’s 50-day moving average is $113.50 and its 200 day moving average is $99.29. The firm has a market cap of $6.14 billion, a P/E ratio of 23.05 and a beta of 0.59. Icon Plc has a 52-week low of $73.76 and a 52-week high of $117.53.
TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Icon Plc (ICLR) to Post $1.32 EPS” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/21/analysts-anticipate-icon-plc-iclr-to-post-1-32-eps.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WCM Investment Management CA increased its holdings in Icon Plc by 6.8% in the 2nd quarter. WCM Investment Management CA now owns 3,965,106 shares of the medical research company’s stock worth $387,747,000 after buying an additional 252,853 shares in the last quarter. FMR LLC increased its holdings in Icon Plc by 38.4% in the 2nd quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock worth $224,037,000 after buying an additional 635,950 shares in the last quarter. Wasatch Advisors Inc. increased its holdings in Icon Plc by 0.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,850,244 shares of the medical research company’s stock worth $180,935,000 after buying an additional 13,104 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Icon Plc by 45.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,594,656 shares of the medical research company’s stock worth $127,126,000 after buying an additional 496,700 shares in the last quarter. Finally, Boston Partners increased its holdings in Icon Plc by 3.4% in the 2nd quarter. Boston Partners now owns 1,208,640 shares of the medical research company’s stock worth $118,193,000 after buying an additional 40,153 shares in the last quarter. Institutional investors own 91.54% of the company’s stock.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.